Regorafenib as a new standard of care in advanced colorectal cancer

摘要

Standard treatment for metastatic colorectal cancer (mCRC) involves chemotherapy based on fluoropyrimidines, oxaliplatin, irinotecan and treatments targeting the angiogenic pathway, and EGFR in RAS wild-type tumors. Regorafenib, an active multikinase inhibitor, demonstrated activity against mCRC in Phase I and II studies. The CORRECT study demonstrated activity of regorafenib in third line versus placebo. The primary end point (overall survival), was met (6.4 vs 5.0 months [hazard ratio: 0.77; 95% Cl: 0.64-0.94; p = 0.0052]). Median progression-free survival was 1.9 versus 1.7 months (hazard ratio: 0.49; 95% Cl: 0.42-0.58; p < 0.0001). Most common adverse events of regorafenib were hand-foot skin reaction, fatigue, diarrhea, hypertension and rash or desquamation and stomatitis, but with a close management and/or dose modifications were controlled. In conclusion, regorafenib is a new standard in third line in mCRC.